Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections

Date: April 22, 2019 Issue #:  1570Summary:  Eravacycline (Xerava– Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline (Tygacil, and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacterial drugs; it should be used only when no suitable alternative is available.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Antibacterials Ceftriaxone Doripenem eravacycline Ertapenem Escherichia coli Imipenem/cilastatin Invanz meropenem Merrem methicillin-resistant staphylococcus aureus penicillin Piperacillin/tazobactam Primaxin Pseudomonas aerugi Source Type: research